Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111270 | 1.00 | HPGD (0.36) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20117747 | 0.93 | HPGD (0.36) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20102467 | 0.91 | PTGDR2 (0.37) | HPGDALDH1A1PTGDR2FFAR1KDM1A | |
| SCHEMBL20111449 | 0.91 | HPGD (0.37) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20117676 | 0.91 | HPGD (0.34) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20102392 | 0.89 | HTR2A (0.34) | HTR2AHTR2CHTR2BPTGDR2SSTR5 | |
| SCHEMBL20111302 | 0.89 | HPGD (0.39) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20111318 | 0.88 | HPGD (0.38) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20111715 | 0.88 | HPGD (0.35) | HPGDSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL20117630 | 0.87 | HPGD (0.34) | HPGDSCN9AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | HPGD 4744/4885SCN9A 2846/4885HTR2A 791/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | HPGD 4744/4885SCN9A 2846/4885HTR2A 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.